Background: Non-ampullary duodenal adenocarcinoma, excluding carcinoma in the ampulla of Vater, is a rare disease. Although several prognostic factors have been reported, they remain controversial due to the rarity of non-ampullary duodenal adenocarcinoma. The aims of this study were to investigate prognostic factors in patients with non-ampullary duodenal adenocarcinoma and to assess chemotherapy in patients with recurrence. Patients and methods: Records of 25 patients who underwent surgical treatment for nonampullary duodenal adenocarcinoma from 2004 to 2016 were retrospectively reviewed. The relationship between the clinicopathological factors and outcomes was investigated. Results: Serum level of CA19-9, gross appearance, tumor size, tumor invasion, lymph node metastases, TNM stage and lymphatic and vascular invasion were significant risk factors of recurrence. Patients with recurrence who received chemotherapy according to regimens used to treat colorectal cancer had a better prognosis than those without chemotherapy (P = 0.016). Conclusion: Advanced non-ampullary duodenal adenocarcinoma has a poor prognosis, but chemotherapy possibly improves the prognosis in the patients with recurrent non-ampullary duodenal adenocarcinoma.
Introduction
Non-ampullary duodenal adenocarcinoma (NDA) is one of the small bowel adenocarcinomas (SBAs). It is a rare malignant neoplasm, accounting for 0.5% of all gastrointestinal malignancies and 33-52% of SBAs (1) (2) (3) (4) (5) .
Surgical resection is accepted as a curable treatment for patients with NDA.
Because of the anatomical variety of the duodenum, various operations, such as pancreatoduodenectomy (PD), distal gastrectomy and segmental duodenal resection, have been performed for patients with NDA. However, there is no definitive opinion as to which surgical procedure is best. The 5-year survival rates were reported to range from 23% to 71% in the patients with NDA who underwent surgical resection (6) . Some reports stated that TNM stage, tumor size and location were prognostic factors, but they remain controversial due to the rarity of NDA (7) (8) (9) . Adjuvant and therapeutic chemotherapy for NDA are also controversial (10, 11) . Because of the small population of patients with SBA, there is no evidence on useful chemotherapy regimens to treat it.
The aims of this study were to investigate prognostic factors in patients with NDA and to assess chemotherapy in the patients with recurrence.
Patients and methods

Patients
Twenty-five patients who underwent surgical treatment in the Department of Gastroenterological and Pediatric Surgery, Oita University from 2004 to 2016 were enrolled in this study. All patients had a primary tumor located in the duodenum. Patients with tumors arising from the ampulla of Vater, bile duct, pancreas and stomach were excluded. Only the patients with pathologically confirmed NDA were enrolled.
Clinicopathological features including patient characteristics, operative procedure, pathological findings and adjuvant chemotherapy were examined retrospectively and outcomes of patients with recurrence were also reviewed. We followed the ethical principles stated in the guidelines of the World Medical Association's Declaration of Helsinki in this study. This study was approved by the ethics committee of Oita University Faculty of Medicine.
Statistical analysis
We investigated the relationship between the perioperative factors and recurrence using the Student t-test for continuous variables and the chi-square test for categorical variables. We included the following 18 perioperative factors in the analyses-patient characteristics: age, sex, body mass index, symptoms, serum levels of CEA and CA19-9; operative findings: surgical procedure (PD/others), operation time, blood loss and pathological findings: location (first/ second/third or fourth), gross appearance, size, differentiation, T-stage, N-stage, stage, lymphatic invasion and venous invasion.
All variables are expressed as mean ± standard deviations for continuous data. Survival probabilities after surgery were calculated by the Kaplan-Meier method and analyzed by the log-rank test. Statistical significance was defined as P < 0.05. All statistical analyses were performed using JMP 11 (SAS Institute Inc., Cary, NC, USA).
Results
Clinicopathological features
Of the 25 patients with a mean age of 63.5 ± 12.7 years, 17 were women and 8 were men (Table 1) . Serum levels of CEA and CA19-9 were elevated in 4 (16%) and 4 (16%) patients, respectively. Tumors were located at the first portion of the duodenum in 8 patients (32%), the second portion in 14 (56%), and the third and fourth portions in 3 (12%). PD was performed in 19 (76%) patients, distal gastrectomy in 1 (4%), partial duodenectomy (segmental resection) in 2 (8%) and local resection (wedge or mucosal resection) of the duodenum in 3 (12%).
The mean tumor diameter was 35.7 ± 20.9 mm, and the depth of tumor invasion was T1 in 10 (40%) patients, T3 in 6 (24%) and T4 in 9 (36%). Eleven patients (44%) had lymph node metastases. Ten patients (40%) were classified as stage 1; 4 (16%) as stage 2 and 11 (44%) as stage 3. Adjuvant chemotherapy (S-1 or capecitabin) was administered in 8 patients (32%), all of whom had stage 2 or 3 NDA.
Post-operative course and risk factors for recurrence
Ten of the 25 patients (41.7%) experienced recurrence of their cancer. Serum level of CA19-9, gross appearance, tumor size, tumor invasion, lymph node metastases, TNM stage, lymphatic and vascular invasion and adjuvant chemotherapy were significant risk factors for recurrence (Table 2 ). However, adjuvant chemotherapy was performed only for patients with advanced NDA, and thus selection bias might have influenced this result. 
PD, pancreatoduodenectomy; DP, distal gastrectomy; PRD, partial resection of duodenum; LR, local resection. 
Survival after surgery
The 5-year survival rate in the 25 patients was 52% (Fig. 1) . The mean time to recurrence after surgery was 18.0 ± 12.5 months in the 10 patients with recurrence (Table 3) . Local recurrence occurred in 3 (30%) patients, lymph node metastases in 4 (40%), liver metastasis in 2 (20%) and peritoneal dissemination in 4 (40%). Chemotherapy was performed in five patients (50%), and two of the patients received second-line chemotherapy. There were no significant differences in clinicopathological features between patients who received chemotherapy and those who did not receive it (Table 4) . Mean survival time from recurrence was 8.2 ± 10.4 months (Fig. 2a) , and the five patients who received chemotherapy had a better prognosis than the other five patients (P = 0.016) (Fig. 2b ).
Discussion
Our retrospective study revealed that serum level of CA19-9, gross appearance, tumor size, tumor invasion, lymph node metastases, TNM stage and lymphatic and vascular invasion were risk factors for the recurrence of NDA after surgery. Operative procedures were not associated with the recurrence, and advanced NDA recurred frequently. Although this study included patients with early-stage NDA, the 5-year survival rate was as low as 52%. Some retrospective studies showed younger age, advanced TNM stage, poor differentiation and positive margin to be associated with poor prognosis (4-7). Especially, lymph node status is an important prognostic factor, and patients with advanced NDA have a poor prognosis (12) . NDA, excluding carcinoma in the ampulla of Vater, is a rare disease. Previous studies showed that the incidence of NDA ranged from 3.7 to 5.4 cases per 1 million persons by year (13, 14) . NDA is considered to be an SBA. Half of all SBAs arise from the duodenum, most commonly in the descending duodenum, 30% from the jejunum and the remaining 20% from the ileum (15) . Tumors located in the descending duodenum accounted for 56% of the cases in our study.
Various operations are performed for patients with NDA according to the tumor sites. PD is often performed for patients with NDA located in the first and second portions of the duodenum, whereas the operative procedure for NDA located in the third and fourth portions is controversial. Some reports stated that all NDAs should be treated with PD because of lymph node dissection (5, 16) . However, others stated that PD offered no oncological benefit compared with partial resection for NDA located in the third and fourth portions of the duodenum (17) (18) (19) (20) . Partial resection of the duodenum may lead to less morbidity and mortality than PD. Curative resection of NDA with a negative margin is a significant prognostic factor (6) . Several studies found significantly better survival in the patients without lymph node metastasis compared with those with it (21, 22) . However, local resection has been considered to be adequate treatment for early-stage NDA, and we performed it in three patients. Recent reports showed that laparoscopic-endoscopic cooperative surgery for early NDA was safe and effective, resulting in an adequate surgical margin and minimal invasiveness (23, 24) .
Adjuvant therapy has not had a significant impact on recurrence or overall survival. In our data, adjuvant chemotherapy did not correlate with recurrence rate or prognosis in the patients with NDA except for those at an early stage (data not shown). Because of the rarity of NDA, the chemotherapy regimens to treat it have also not been studied well. There are some retrospective studies on SBA showing that on the basis of immunophenotypic pattern, molecular characteristics and genome-wide DNA copy number aberrations, it is more similar to colorectal cancer than to gastric cancer (25) . Therefore, the chemotherapy regimens for colorectal cancer were usually used for the treatment of SBA (26, 27) . We also used chemotherapy regimens for colorectal cancer to treat recurrent NDA in this patient series, and the patients who received chemotherapy had a better prognosis than those who did not receive it. This is a retrospective study, and its sample size is small due to the rarity of NDA. Therefore, it is difficult to perform sufficient analyses such as multivariate analysis, and further studies are thus required to confirm these results in a larger cohort of patients with NDA.
In conclusion, advanced NDA has a poor prognosis, and chemotherapy according to that used to treat colorectal cancer possibly improves the prognosis in the patients with recurrent NDA.
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